Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TUB-030 · 1 trial · 6 indications
The highest dose is defined at which no more than 1 of 3 patients have had a Dose Limiting Toxicity (DLT) according to NCI CTCAE V5.0 criteria
| Arm | Type | Description |
|---|---|---|
| Phase 1: dose escalation | EXPERIMENTAL | Drug TUB-030, administered by intravenous (IV) infusion |
| Phase 2: dose optimization in NSCLC and HNSCC | EXPERIMENTAL | Drug TUB-030, administered by intravenous (IV) infusion NSCLC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion HNSCC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion |
| Name | Type | Description |
|---|---|---|
| TUB-030 | DRUG | A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle |
Inclusion Criteria: 1. Male or non-pregnant, non-breastfeeding female aged 18 years or older 2. Adequate organ function 3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or investigational drugs must have had ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TUB-030 is an investigational small molecule antibody-drug conjugate being developed by Gilead Sciences, Inc. for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is not yet approved for any indication. The program is in oncology.
TUB-030 is being studied in adults with advanced solid tumors, including head and neck squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, and colorectal cancer. It is investigational and has not been approved for any use.
TUB-030 targets 5T4, a tumor-associated antigen. It is an antibody-drug conjugate, meaning the targeting portion binds 5T4 and delivers a cytotoxic payload to cells expressing that target. This mechanism is designed to concentrate anti-tumor activity on 5T4-positive tumor cells.
TUB-030 is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. Gilead is the sponsor of the clinical program evaluating the drug in advanced solid tumors.
TUB-030 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 program is currently recruiting participants.
TUB-030 is being evaluated in a first-in-human Phase 1 study, NCT06657222, titled a First in Human Study of TUB-030 in Patients With Advanced Solid Tumors. The trial is recruiting, has an enrollment of 250 participants, and is running in the United States, Canada, France, Romania, and Spain.